Moderna's experimental vaccine was 94.5 per cent effective in preventing COVID-19 based on interim data from a late-stage trial, the company said on Monday, becoming the second US drugmaker to report results that far exceed expectations.

Together with Pfizer's vaccine, which is also more than 90 per cent effective, and pending more safety data and regulatory review, the United States could have two vaccines authorised for emergency use in December with as many as 60 million doses of vaccine available this year.

Reuters